Dr. Patricia A. Defusco, MD

Dr. Defusco practices at Hartford Hospital in Hartford, Connecticut, part of Hartford HealthCare.

Dr. Defusco's NPI, 1851496061, was assigned on September 13, 2006. Dr. Defusco graduated from Boston University School of Medicine in 1980. Dr. Defusco holds Connecticut license 023881.

Dr. Defusco's primary practice is Hartford Hospital, at 80 Seymour Street, Hartford, CT 06102 in Hartford County. The practice phone is (860) 545-5000.

Dr. Defusco's primary practice is Hartford Hospital in Hartford, Connecticut, part of Hartford HealthCare. The medical group on file is Hartford Hospital. Dmand AI also links Dr. Defusco to 1 more hospital, 4 medical groups and 1 group practice or clinic, each named with a free account. Dr. Defusco's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Defusco practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Defusco's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Defusco is licensed in Connecticut.

CMS data shows 399 Medicare services from Dr. Defusco across 3 procedure codes in 2024, all of them office visits, for 212 Medicare patients. Medicare paid $24,426 for them. Every service was in an office.

CMS counts 212 Medicare patients who saw Dr. Defusco in 2024. The largest group is 75 to 84, with 95 patients. 75% of them have cancer, and 75% have high cholesterol. 8% are also on Medicaid. Their average risk score is 1.33, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Defusco's median patient age at 69, with 95% women.

In 2024, Dr. Defusco wrote 916 Medicare Part D claims for 194 patients. 85% of them were for generic drugs. CMS names the drug for 771 of them, across 15 drugs with 11 or more claims each, at $1,480,530 in total drug cost. In 2023, CMS named 739 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Defusco for performance year 2024, reported as part of a group. Dr. Defusco accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Defusco as offering telehealth.

Dmand AI links 10 papers to Dr. Defusco, published from 2012 to 2024. 2021 was the busiest year, with 2. The most frequent topics are Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Paclitaxel. Dr. Defusco has published most often in Breast Cancer Res. Dr. Defusco's most frequent co-authors are Vandana Gupta Abramson, MD, Blair Ardman, MD and Ron Bose, MD.

Dmand AI links Dr. Defusco to 5 clinical trials, 3 of them phase 3 studies. 4 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Carcinoma, Intraductal, Noninfiltrating. National Cancer Institute (NCI) sponsors the most, 2.

CMS Open Payments shows 82 general payments to Dr. Defusco from 15 drug and device companies from 2016 to 2021. Food and beverage make up the largest share, 98% of the total. Novartis Pharmaceuticals Corporation paid the most, $372.

Dr. Defusco graduated from Boston University School of Medicine in 1980.